NEW YORK ( TheStreet) -- Shares of Geron Corporation (Nasdaq: GERN) were gapping down Tuesday morning with an open price 20.5% lower than Monday's closing price. The stock closed at $2.20 Monday and opened today's trading at $1.75.

The average volume for Geron has been 1.4 million shares per day over the past 30 days. Geron has a market cap of $299.8 million and is part of the health care sector and drugs industry. Shares are down 57.6% year to date as of the close of trading on Monday.

Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.

TheStreet Ratings rates Geron as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. You can view the full Geron Ratings Report.

Get more investment ideas from our investment research center.

Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.

If you liked this article you might like

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Premarket Movers: Innoviva, Akebia, Geron

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Geron (GERN) Stock Rises on $80 Million Janssen Licensing Deal